Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Imagine a world where managing type 2 diabetes doesn't involve needles. A new experimental pill might just change the game, ...